Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
Titel:
Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study
Auteur:
Kadowaki, Takashi Haneda, Masakazu Inagaki, Nobuya Terauchi, Yasuo Taniguchi, Atsushi Koiwai, Kazuki Rattunde, Henning Woerle, Hans J. Broedl, Uli C.